Venereology (SEXUALLY TRANSMITTED INFECTIONS) with Ina Park

Episode Summary

Executive Summary: Allie Ward interviews Dr. Ina Park about sexually transmitted infections, stigma, testing, treatment, and prevention. The episode reframes STDs as STI/SDI, explains what’s curable versus lifelong, clarifies testing schedules by population, highlights evolving science around herpes and bacterial vaginosis, and strongly advocates HPV vaccination, routine screening, partner treatment, and open communication to reduce shame and transmission.

Main Topics: Language shift: STD to STI and the stigma around sex (Priority: 5/5): Dr. Park explains why the field moved from venereal disease to STD to STI: many infections are asymptomatic, not all cause disease, and older terms carry moral judgment. The conversation emphasizes that STI stigma is cultural, not medical, and that sex is easier to do than to discuss. Testing guidance and who should screen, when (Priority: 5/5): Testing frequency depends on sexual practices, partners, anatomy, and network risk. The episode outlines routine screening for younger sexually active people, more frequent testing for people with multiple partners or in higher-risk sexual networks, and site-specific swabbing for throat, rectum, and urine/genital testing. Bacterial, viral, and parasitic infections: treatment differences (Priority: 4/5): The episode distinguishes curable bacterial/parasitic STIs (gonorrhea, chlamydia, syphilis, trichomonas, some mycoplasma cases) from lifelong viral infections (HSV, HIV, hepatitis B), while noting hepatitis C is now curable and that antibiotic resistance is an emerging issue for mycoplasma genitalium. Herpes realities: prevalence, shedding, disclosure, and triggers (Priority: 5/5): Dr. Park stresses that herpes is common, often mild or asymptomatic, and highly stigmatized relative to its actual burden. She explains HSV-1/HSV-2 site overlap, shedding patterns, suppression therapy, barriers, disclosure, and how trauma or immune stress can trigger outbreaks. BV as a sexually transmissible condition and partner treatment (Priority: 5/5): The episode highlights a paradigm shift: recurrent bacterial vaginosis may often be maintained by partner exchange of bacteria. New trial evidence suggests treating male partners alongside patients can reduce recurrences, challenging the idea that BV is solely the patient’s problem. HPV vaccine advocacy and cancer prevention (Priority: 5/5): Dr. Park strongly endorses HPV vaccination as one of the most important cancer-prevention tools available, noting reductions in precancer, expanded age eligibility, improved dosing schedules, and broad protection against cervical, anal, penile, and some head/neck cancers. Public health, access, and policy threats (Priority: 4/5): The conversation addresses funding cuts, political interference with CDC content, reduced clinic staffing, and the risk that weakened public health infrastructure could reverse gains in STI prevention, treatment, and HIV elimination efforts.

Key Arguments: STI is the more scientifically accurate term because many infections do not cause disease and may never produce symptoms. Stigma around STIs is driven by moral judgments about sex, especially in cultures influenced by heteronormative or religious norms. Testing should match anatomy, behavior, and partner networks; high-frequency screening is appropriate for people with multiple partners and higher-risk networks. Open communication and negotiated non-monogamy can lower risk because testing and disclosure are more likely to happen. Herpes is common and manageable; it is not a reason for shame, and suppression/barrier methods can reduce transmission even if they do not eliminate it. BV recurrence may require treating both partners, signaling that the condition can be sexually transmissible rather than purely individual. HPV vaccination is a major cancer-prevention intervention with excellent safety data and expanding indications. Undiagnosed STIs can cause pelvic inflammatory disease, infertility, and cancer, making regular screening a preventative health issue rather than a moral one. HIV outcomes have transformed: with treatment, undetectable equals untransmittable, and PrEP provides multiple preventive options for HIV-negative people. Public-health funding and nonpartisan access to CDC guidance are essential for maintaining STI care, vaccine confidence, and research progress.

Data Points: HPV-related cancers in the U.S.: ~36,000 cases/year - Cancers attributed to oncogenic HPV types include cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers. HPV natural clearance: Most active infections clear within 2 years - Used to reassure listeners that HPV infection is often transient. HPV vaccine dosing under age 14: 2 doses instead of 3 - Updated vaccination schedule discussed by Dr. Park. Potential one-dose HPV protection: 1 shot may be enough - A recent NEJM article suggested one dose might provide long-term protection against HPV 16 and 18. HPV vaccine age range: Licensed ages 9 to 45 - Dr. Park emphasized vaccination can still help adults up to 45. Cervical precancer decline: Huge declines among women ages 20–24 - Population-level HPV vaccine impact described from Dr. Park’s research. HSV-1 prevalence in U.S. adults: About 50% have antibodies - Explains how common oral herpes exposure is. HSV-1 prevalence in low- and middle-income countries: Closer to 80% - Shows global variation in HSV-1 exposure. HSV-2 prevalence: Up to 20% of the population - Used to explain why genital herpes is common but often hidden. HSV-1 genital shedding after first outbreak: 12% of days at 2 months; 7% of days nearly 1 year later - JAMA paper cited to show shedding declines over time but can remain asymptomatic. Suppressive herpes medication effect: About 50% reduction in transmission risk - Valacyclovir and similar suppressive therapy discussed. Barrier protection for herpes: Over 80% risk reduction in some studies - Condom/barrier use can substantially reduce transmission, especially with penile lesions. Untreated infertility burden: 9% infertility rate in reproductive-age females - 2017 AJOG study referenced in relation to STI-caused tubal factor infertility. Circumcision and STI prevention: HIV up to 60%, HSV-2 up to 34%, HPV 35%, trichomonas nearly 50% - 2010 JAMA Pediatrics study cited in the circumcision discussion. Male-partner BV treatment trial size: Over 150 couples - 2025 NEJM partner-treatment study that stopped early due to strong effect. HIV treatment principle: Undetectable = untransmittable (U=U) - Explains modern HIV prevention and why treated HIV does not progress to AIDS. PrEP options: Daily pills, event-driven pills, 2-month injectable, 6-month injectable, and an anticipated 12-month injectable - Current and emerging HIV prevention options described.

Pivotal Quotes: "having sex is a lot easier than talking about sex" — Dr. Ina Park: Explaining why STI stigma persists even though sex is common and culturally normalized in many settings "your partner didn't get an STD from the toilet seat, they just cheated on you" — Dr. Ina Park: Favorite myth-busting example about transmission misconceptions "I just want folks to know I vaccinated my own kids and I tell people that all the time if they ask" — Dr. Ina Park: Strong endorsement of HPV vaccination safety and importance

Implications: Listeners are encouraged to treat STI care like routine preventive health: get vaccinated, test appropriately, disclose openly, and seek evidence-based care. For public health, funding stability, partner treatment, and vaccine access are critical to preserving gains against STIs, infertility, cancers, and HIV.